In a swift resolution to a patent dispute in the competitive percussive massage device market, Hyper Ice, Inc. and its IP holding entity Hyperice IP Subco, LLC voluntarily dismissed without prejudice all patent infringement claims against rival Therabody, Inc. just 54 days after filing in the Delaware District Court. Filed on January 3, 2024, and closed on February 26, 2024, the action centered on U.S. Patent No. 11,857,482 B1, covering battery-powered percussive massager technology. The dismissal was executed under Fed. R. Civ. P. 41(a)(1)(A)(i) before Therabody filed any answer or motion for summary judgment.

This rapid voluntary dismissal carries significant strategic weight for IP professionals and litigation counsel operating in the fast-growing consumer wellness technology space. Whether driven by pre-suit licensing discussions, claim scope reassessment, or strategic repositioning, the outcome leaves all options open for Hyperice to refile — and signals that companies in the percussive therapy market face escalating patent assertion pressure. R&D teams and portfolio managers at competing device makers should treat this case as an early indicator of where IP enforcement boundaries are being drawn.

Case Overview

The Parties

The Patent at Issue

U.S. Patent No. 11,857,482 B1 covers technology related to battery-powered percussive massagers — handheld devices that deliver rapid, repetitive pressure to muscles for recovery and pain relief. The patent’s claims likely address specific mechanical, electronic, or ergonomic innovations that distinguish Hyperice’s Hypervolt-style devices from prior art. In practical terms, the patent protects engineering choices in how these devices deliver percussive force, manage battery power, or control motor actuation — core functional elements that competitors like Therabody must design around.

• • US11857482B1

Legal Representation

Plaintiff Counsel: Lewis Brisbois Bisgaard & Smith LLP (lead: Aimee M. Czachorowski)
Defendant Counsel: Morris, Nichols, Arsht & Tunnell LLP (lead: Karen Jacobs)

Litigation Timeline & Procedural History

This case was filed in the U.S. District Court for the District of Delaware, one of the most strategically chosen venues in U.S. patent litigation alongside the Eastern District of Texas. Delaware’s well-developed patent case law, experienced judiciary, and familiarity with complex IP disputes make it a preferred forum for technology companies — particularly those incorporated in Delaware, as many major U.S. corporations are. The case was assigned to Chief Magistrate Judge Jennifer L. Hall, reflecting Delaware’s efficient case management infrastructure for patent matters at the first-instance district court level.

At just 54 days from filing to closure, this case represents an exceptionally brief litigation lifecycle — well below the average patent case duration of 2–3 years. The termination came via voluntary dismissal under Fed. R. Civ. P. 41(a)(1)(A)(i), a mechanism available only before the defendant files an answer or a motion for summary judgment. This timing is legally significant: because Therabody had not yet responded on the merits, Hyperice was entitled to dismiss as of right, requiring no court approval. The dismissal without prejudice means the case can be refiled, suggesting the parties may have entered licensing negotiations, that claim scope is being reexamined, or that Hyperice is repositioning for a stronger re-assertion.

The Verdict & Legal Analysis

Outcome

The case was terminated on February 26, 2024, via Plaintiffs’ Notice of Voluntary Dismissal Without Prejudice pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i). No damages were awarded, no injunctive relief was granted, and no judgment on the merits was entered. Because the dismissal was without prejudice, Hyper Ice, Inc. and Hyperice IP Subco, LLC retain the full right to refile infringement claims against Therabody, Inc. based on U.S. Patent No. 11,857,482 B1 at a later date.

Verdict Cause Analysis

The following factors are relevant to understanding why this infringement action concluded via voluntary dismissal rather than adjudication on the merits:

• Hyperice filed the dismissal before Therabody submitted any answer or motion for summary judgment, preserving the right to dismiss as of right under Rule 41(a)(1)(A)(i) without requiring judicial approval or triggering any cost-shifting.
• A dismissal without prejudice, particularly one this rapid, often signals ongoing or newly initiated settlement or licensing discussions between the parties, where litigation is paused as leverage while commercial terms are negotiated.
• The 54-day window may also reflect a post-filing claim chart or prior art review that prompted Hyperice’s counsel to reassess the strength of specific infringement contentions before incurring full litigation costs.
• Structuring the plaintiff side as both Hyper Ice, Inc. and its IP subsidiary Hyperice IP Subco, LLC suggests a deliberate portfolio management architecture — the dismissal may reflect internal strategic recalibration of how and through which entity future enforcement proceeds.

Legal Significance

1. 1. Because no answer was filed and no merits determination was made, this dismissal creates no estoppel or preclusive effect — Hyperice retains a clean slate to refile the same claims, assert different claims from the same patent, or expand to additional patents in a future action.
2. 2. The use of an IP holding subsidiary (Hyperice IP Subco, LLC) as a co-plaintiff is a structurally significant indicator of how consumer hardware companies are increasingly ring-fencing their patent assets for enforcement purposes, a trend that litigators and in-house counsel in this space should monitor closely.
3. 3. For companies in the percussive therapy and broader consumer recovery device market, this case confirms that U.S. Patent No. 11,857,482 B1 is an active enforcement asset — even though no infringement finding was made, the filing signals Hyperice’s willingness to assert its portfolio aggressively, which has direct implications for competitor FTO clearance obligations.

Strategic Takeaways

For Patent Attorneys:

• When a client files under Rule 41(a)(1)(A)(i) this quickly, ensure the dismissal is explicitly without prejudice and confirm the defendant has not filed any paper that would require court consent — a misstep here could trigger involuntary dismissal with prejudice or cost exposure.
• The use of an IP holding subsidiary as co-plaintiff requires careful standing analysis at the outset; confirm ownership chain and exclusive licensing structures are airtight before filing to avoid standing challenges on refile.
• In fast-moving consumer hardware disputes, consider whether a pre-suit licensing letter or demand paired with a shorter litigation hold period could achieve commercial outcomes more efficiently than immediate district court filing, especially in Delaware where docket costs accumulate quickly.
• Monitor US11857482B1 for any post-grant proceedings (IPR or ex parte reexamination) that Therabody may initiate as a defensive countermove following this dismissal, as defendants in voluntarily dismissed cases often use the intervening period to challenge patent validity at the USPTO.

For IP Professionals:

• In-house IP teams at companies competing in the percussive massager and recovery device space should immediately flag US11857482B1 for FTO review — its active enforcement status, combined with a dismissal without prejudice, means re-assertion is a live risk that product roadmap planning must account for.
• The Hyperice IP Subco, LLC structure is a signal to review your own patent portfolio segregation strategy: housing enforcement assets in a dedicated IP entity can provide litigation flexibility, tax efficiency, and risk insulation from the operating company — a model worth evaluating for hardware IP portfolios.

For R&D Teams:

• Engineering teams developing battery-powered percussive or vibration-based therapy devices should conduct a targeted claim mapping exercise against US11857482B1 to identify any feature overlap and document design-around decisions before product finalization.
• Given that this patent was granted in January 2024 (as a B1 issue), it reflects recent USPTO allowance standards — R&D leaders should review the prosecution history for insight into which claim elements were deemed novel and non-obvious, as those elements define the highest-risk design zones for competing products.